A randomised, double-blind, active placebo-controlled, parallel groups, dose-response study of scopolamine hydrobromide (4–6 μg/kg) in patients with major depressive disorder

Table 1 Full inclusion criteria

	Inclusion criteria
Consent	Willing and able to give informed consent for participation in the trial
Demographics
Age	18–60 years
Sex	Male or female
Mental health
Diagnosis	Major depressive disorder according to DSM-V criteria
Duration	Greater than 2 weeks
MADRS	≥ 20 (i.e., moderate to severe depression)
Treatment status	Antidepressant medication free for at least 2 weeks (or 4 weeks if previously on fluoxetine)

ISSN: 1745-6215